NCT02841748: A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Sponsor: University of Chicago. Phase: PHASE2. Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck